The company has announced the decision to stop the once-weekly injectable semaglutide kidney outcomes trial FLOW based on interim analysis.
The trial has studied the effect of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease.
Based on a recommendation from the independent Data Monitoring Committee
The decision to stop the trial is based on a recommendation from the independent Data Monitoring Committee (DMC) concluding that the results from an interim analysis met certain pre-specified criteria for stopping the trial early for efficacy.
Based on the decision to stop the trial at interim, the process of closing the trial will be initiated, states the company. To protect the integrity of the trial, Novo Nordisk remains blinded to the results until trial completion.
Novo Nordisk expects that FLOW will read out during the first half year of 2024.
Photo: Novo Nordisk headquarters